Sertraline for PMDD: Four Checks Before Discussing Symptom-Onset Dosing

Bring your symptom diary to a PMDD treatment review and ask which days a proposed prescription would cover. “Intermittent” needs an agreed start and stop rule. The current US sertraline label describes a luteal-phase schedule beginning 14 days before the anticipated period.¹

Our PMS and PMDD guide explains the broader assessment and treatment discussion.

Check who entered the symptom-onset trial

The 2015 trial randomized 252 women aged 18–48 after prospective PMDD assessment over at least two cycles. Participants took sertraline or placebo from symptom onset into the first days of menstruation for six cycles. Current major depression and bipolar disorder were excluded.²

This was a placebo comparison, not a direct comparison with daily or full luteal-phase dosing.²

Check the primary outcome before the response percentage

The primary Premenstrual Tension Scale (PMTS) result did not differ significantly between groups (P=.06). Secondary anger/irritability ratings favored sertraline. Clinician-rated response occurred in 77/115 (67.0%) versus 65/124 (52.4%), using available last-visit ratings carried forward. Response was not the same as remission.²

NIMH supported the study; Pfizer donated medicine and placebo.²

Check which part of daily functioning improved

A 2023 secondary analysis of the same trial, using 184 participants’ data, examined functioning after two cycles. Relationship interference improved more with sertraline: the adjusted difference was about 0.4 points on a 1–6 scale. Productivity and hobbies/social activities did not show statistically significant treatment differences. The trial was designed around symptom outcomes, rather than powered specifically for functioning. This analysis should not be counted as a second independent trial.³

For your own review, name the problem you want treatment to change: arguments with a partner, unfinished work, cancelled plans or another recurring difficulty. Record that alongside symptom scores, rather than relying on one general rating of the month.

Check the prescription’s start, stop and safety instructions

The current US label describes daily or luteal-phase dosing, with luteal treatment continuing through menstruation’s onset. Starting only when symptoms appear is a different schedule. Ask whether that approach fits your diagnosis and prescription.¹

The short-course trial found no excess withdrawal symptoms between groups.² That finding does not establish how someone taking sertraline continuously should stop it. The label advises gradual dose reduction whenever possible and warns about discontinuation reactions.¹

It also calls for bipolar screening and monitoring for clinical worsening or suicidal thoughts. Aspirin, NSAIDs and anticoagulants can increase bleeding risk when taken with sertraline; include period-pain medicines in the medication review.¹

Put the agreed plan in writing

Ask: “Which symptoms should trigger the first dose? When exactly do I stop? What if my period arrives later than expected, or symptoms continue afterward? Who do I contact about side effects?” Use your prescriber’s answers to write the plan and review date.

The Visit Script in Period, Handled offers prompts for describing when a change began, what it stopped you doing and the question you want answered. It can help organize the conversation; this article supplies the PMDD trial details.